Welcome
Support Centre
09 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised controlled study of the effectiveness of a Cognitive Behaviour Therapy (CBT) CD Rom self-help treatment for depression compared with a widely-used Patient Information leaflet when offered to patients on a waiting list for a clinical psychology service
ISRCTN ISRCTN23491839
ClinicalTrials.gov identifier
Public title A randomised controlled study of the effectiveness of a Cognitive Behaviour Therapy (CBT) CD Rom self-help treatment for depression compared with a widely-used Patient Information leaflet when offered to patients on a waiting list for a clinical psychology service
Scientific title
Acronym N/A
Serial number at source 04/S0701/77
Study hypothesis 1. Patients using the Overcoming Depression CBT CD Rom will:
1.1. Have improved mood measured on the Beck Depression Inventory (BDI-II)
1.2. Have improved symptoms and social functioning measured on the Clinical Outcome Measure in Routine evaluation - Outcome Measure (CORE-OM)
1.3. Have lower health care costs
1.4. Have improved knowledge of the causes and treatment of depression
1.5. Need less subsequent sessions of face to face specialist psychological treatment in the Psychology service compared to the control group receiving the Patient Information leaflet
2. The CD Rom self-help will be more acceptable to patients than the short information leaflet
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Depression
Participants - inclusion criteria Patients are offered the CD Rom and are eligible for the study when they have symptoms of depression (including depression and anxiety), and are willing and able to use the materials (i.e. have no visual or reading or hearing problems, learning difficulties and are able to read and understand the spoken English language).
Participants - exclusion criteria Patients who do not wish to use the CD Rom approach, or who have current drug/alcohol abuse/dependency will be excluded from the study. Patients with suicidal intent (score of 2 or more on the BDI-II suicidal thoughts item) and impaired concentration and motivation (as measured by a score of 7 or more on the combined BDI II items for energy, concentration difficulty and tiredness - items 15, 19 and 20 on the BDI-II) will be excluded from the study. In addition, patients with scores lower than 5 or higher than 19 on the Patient Health Questionnaire (PHQ) will not be offered the CD Rom self-help approach and will be excluded from the study.
Anticipated start date 01/01/2005
Anticipated end date 30/06/2007
Status of trial Completed
Patient information material
Target number of participants 92 in each arm = 184 in total
Interventions 1. In the Patient Information leaflet arm, a short information leaflet (Depression – by the British Association for Behavioural and Cognitive Psychotherapies) is given to the patient by the Support Nurse and the content is gone through in a face to face support session lasting 30-40 minutes. A second final support session lasting 20-30 will then be arranged about three weeks later.
2.. In the CBT CD Rom arm, 6 sessions of approximately 45 minutes are delivered by the CD rom. In addition a formal protocol is used to describe the three face to face support sessions that are offered. After the initial session the patient notes their unique user-name and can book in to use the package for up to an hour once a week. After the 3rd and final (session 6) treatment sessions on the computer, a brief review of progress (25-30 minutes) will be offered.
Primary outcome measure(s) Comparison between the Beck Depression Inventory - II scores for the two randomised groups using a 2 sample 2-sided t-test at 2, 4 months and 12 months.
The 4 month outcome is the primary outcome measure.
Secondary outcome measure(s) Further analyses that adjust the treatment effect for a pre-specified set of baseline covariates thought to be of influence on the treatment effect such as use of antidepressants, other self-help materials, and the chronicity of depression using Normal Linear models, will be considered. Secondary analyses will examine the impact of treatment on the total and the four main CORE domains (well-being, symptoms, life functioning and risk), and also patient knowledge, and the cost implications of use, and patient and practitioner perspectives of the effectiveness and acceptability of the treatment approaches. The approach by Jacobson et al, (1991) to present change in the group under study at the level of the individual will also be used. Categorical data will be compared between the two groups using chi-squared tests and logistic regression to adjust for covariates.
Sources of funding Internal NHS Greater Glasgow funding from the SPIRIT project (UK) (code 001 1837)
Trial website
Publications
Contact name Dr  Christopher  Williams
  Address Psychological Medicine
Gartnavel Royal Hospital
1055 Great Western Road
  City/town Glasgow
  Zip/Postcode G12 0XH
  Country United Kingdom
  Tel +44 (0)141 2113912
  Email chris.williams@clinmed.gla.ac.uk
Sponsor NHS Greater Glasgow (UK)
  Address Research Manager
Research and Development Directorate
Gartnavel Royal Hospital
1055 Great Western Road
  City/town Glasgow
  Zip/Postcode G12 0XH
  Country United Kingdom
  Tel +44 (0)141 211 3661
  Fax +44 (0)141 2113814
  Email brian.rae@gartnavel.glacomen.scot.nhs.uk
Date applied 01/09/2005
Last edited 22/09/2009
Date ISRCTN assigned 09/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central